Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs UB 312 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors United Neuroscience
- 07 Mar 2024 Results from this trial presented a Vaxxinity media release.
- 07 Mar 2024 According to a Vaxxinity media release, results from this trial presented by Jean-Cosme Dodart, PhD, SVP of Research in an oral session at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimers and Parkinsons Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024.
- 13 Feb 2024 According to a Vaxxinity media release, clinical data from this study will be presented at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal.